we should say the panels were put on by two professors, professor dworkin of the university of rochest and dennis turk of the university of washington. the emails craig is talking about one the professor was responding to a drug company that said it was too much. he said, quote 20,000 is small change. they buy it easily if they want to be at table. everyone is very happy the meetings. they're getting a huge amount for very little money and they know it. monica, this is tricky because it is a, they are academics who put on these panels. they were bringing together fda firms and pharmaceutical companies. it wasn't an open invitation. you had to pay in ord to be there. they were doing real work that impacted drug companies. they were authoring papers how effective drugs were, how clinical trials should be done. sounds very much like pay to play. what do you think? >> this is a tough issue on one hand i grant this looks bad because the implication somehow the companies are engaged in a pay to play scheme. that they bought their way to the table so they can influence the fda's policies and